Objective:

Background:

Many neurology clinicians face challenges in accurately assessing disease burden and optimizing treatment regimens for patients with gMG. Timely education is critical to ensure they are prepared to incorporate novel FcRn inhibitors into practice.

Design/Methods:

In February 2025, a live virtual continuing education (CE) webinar was provided, with live faculty moderation and question-and-answer sessions. The enduring version of the webinar will remain available through March 25, 2026. Pre- and post-test assessments were used to quantify the impact of education.

Results:

A total of 206 neurology clinicians participated in the education. Clinicians demonstrated limited baseline knowledge across all topics. Regarding assessment, 67% lacked knowledge of tools for gMG assessment and 62% were unfamiliar with the mechanisms of action of FcRn inhibitors. Of note, although 59% of clinicians assessed disease burden before determining treatment options, only 39% evaluated gMG antibody subtype. Baseline awareness of FcRn inhibitors was limited, with only 13% and 25% familiar with clinical evidence of nipocalimab efficacy and rozanolixizumab indication, respectively. These gaps translated into underuse in practice, with 44% of clinicians prescribing complement inhibitors but only 25% reporting experience with FcRn inhibitors. However, post-learning, clinicians were 30% more likely to consider the clinical evidence of FcRn inhibitors when making treatment decisions. Overall knowledge increased by 51%, with 88% of clinicians expressing greater confidence in managing gMG.

Conclusions:

This CE initiative revealed critical gaps in gMG management, particularly in disease assessment and familiarity with FcRn inhibitors. Education significantly improved neurology clinicians’ knowledge and confidence to integrate FcRn inhibitors into treatment decision-making, supporting more informed and personalized patient care.